Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash & Equivalents: 2011-2025

Historic Cash & Equivalents for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to $32.3 million.

  • Enanta Pharmaceuticals' Cash & Equivalents fell 13.25% to $32.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.3 million, marking a year-over-year decrease of 13.25%. This contributed to the annual value of $32.3 million for FY2025, which is 13.25% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Cash & Equivalents stood at $32.3 million for FY2025, which was down 13.25% from $37.2 million recorded in FY2024.
  • Enanta Pharmaceuticals' Cash & Equivalents' 5-year high stood at $85.4 million during FY2023, with a 5-year trough of $32.3 million in FY2025.
  • In the last 3 years, Enanta Pharmaceuticals' Cash & Equivalents had a median value of $37.2 million in 2024 and averaged $51.6 million.
  • In the last 5 years, Enanta Pharmaceuticals' Cash & Equivalents spiked by 94.09% in 2023 and then plummeted by 56.40% in 2024.
  • Enanta Pharmaceuticals' Cash & Equivalents (Yearly) stood at $57.2 million in 2021, then declined by 23.10% to $44.0 million in 2022, then skyrocketed by 94.09% to $85.4 million in 2023, then crashed by 56.40% to $37.2 million in 2024, then fell by 13.25% to $32.3 million in 2025.